Ambispective study reveals rising mortality and inflammatory markers in pediatric hepatitis cases during the pandemic.
Introduction: Severe acute hepatitis of unknown origin in children has become a significant global concern during the SARS-CoV-2 pandemic. This study investigates the epidemiological, clinical, and laboratory characteristics of pediatric hepatitis cases, focusing on possible viral, immune- mediated, or environmental etiologies. Methods: An ambispective observational study was conducted at Minia University Hospital, Egypt, comparing pre-pandemic (March 2016–February 2020) and pandemic/post-pandemic (March 2020– March 2024) pediatric patients with probable acute severe hepatitis (ALT/AST >500 IU/L). Data were obtained from records and prospective follow-up, including serologic/molecular testing and inflammatory biomarkers. Logistic regression models, adjusted for confounders, were used to analyze predictors of adverse outcomes. Results: Among 2,928 children screened, 198 were included (82 pre-pandemic; 116 pandemic/postpandemic). During the pandemic/post-pandemic period, patients had longer hospital stays (median: 6.5 vs. 4.0 days, p<0.001), higher inflammatory markers (IL-6: 28.0% vs. 18.0%, p=0.04; CRP: 34.4% vs. 15.6%, p=0.01), and increased mortality (27.3% vs. 19.5%, p<0.05). SARS-CoV-2 was the predominant virus (52.6%). Elevated IL-6 (OR=3.2), CRP (OR=2.7), and hospital stays >7 days (OR=2.4) predicted adverse outcomes. Discussion: The data suggest that SARS-CoV-2 may contribute to the severity of pediatric hepatitis through immune dysregulation or co-infection with other pathogens. The observed increase in severe cases and systemic complications warrants attention to inflammatory biomarkers for prognosis and intervention planning. Conclusion: Pediatric acute severe hepatitis during the SARS-CoV-2 pandemic has exhibited heightened severity and mortality. Elevated IL-6 and CRP are valuable prognostic markers. Multidisciplinary strategies are essential to better understand this emerging condition and optimize management.
No takes yet. Share an insight, caveat, or question.
Nagwa Mohamed Sabry Mahmoud (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: